chufangao/CTO huggingface dataset:
Clinical trial NCT03654313: Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
Official title: A Phase 1 Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus.
Sponsor: MedImmune LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 88.0 (ACTUAL)
Number of arms: 11.0
Start date: 2018-09-28
Primary completion date: 2020-07-21
Completion date: 2020-07-21
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.~Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT03768505: Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)
Official title: A Multicenter, Open Label Single-Arm, Phase 2 Study of Zandelisib (ME-401) in Subjects With Follicular Lymphoma and Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies (The TIDAL Study)
Sponsor: MEI Pharma, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: discontinuation of zandelisib program
Enrollment: 169.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-06-25
Primary completion date: 2023-03-24
Completion date: 2023-03-24
Limitations and caveats: The study was closed prematurely for business reasons.
Plan to share individual participant data: NO
Clinical trial NCT02243709: Mifepristone for the Prevention of Relapses of Alcohol Drinking
Official title: A Pilot Study on the Safety and Efficacy of Mifepristone for the Prevention of Relapses of Alcohol Drinking
Sponsor: Brown University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 32.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-09-30
Primary completion date: 2021-12-21
Completion date: 2021-12-21
Clinical trial NCT04784897: A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19
Official title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19
Sponsor: Innovation Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 120.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-22
Primary completion date: 2021-07-01
Completion date: 2021-07-30
Baseline population: Study participants were randomized to active or placebo, and dependent upon if prior to or after the scheduled interim safety analysis, were randomized to 3 days or 5 days of study treatment.~Subjects randomized to placebo are pooled for the analyses since duration of placebo should not impact efficacy or safety outcomes. As the different treatment durations for Brilacidin have potential to impact efficacy and/or safety outcomes, 3-dose and 5-dose active arms were analyzed separately.
Plan to share individual participant data: NO
Clinical trial NCT04511975: A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS
Official title: A Phase 1b Study Evaluating the Safety and Efficacy of IBI188 in Combination With Azacitidine in Subjects With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (MDS)
Sponsor: Innovent Biologics (Suzhou) Co. Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: SUSPENDED 
Why stopped: pause for further assessment and study adjustment
Enrollment: 32.0 (ESTIMATED)
Number of arms: 1.0
Start date: 2020-08-24
Primary completion date: 2021-10-31
Completion date: 2022-04-04
Clinical trial NCT04106843: Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
Official title: A Phase II Study to Evaluate the Effects of 177Lu-DOTATATE in Patients With Unresectable and Progressive Rare Metastatic Endocrine Carcinomas: Medullary Thyroid Cancer, Parathyroid Carcinoma, Pituitary Carcinoma, and Malignant Pheochromocytoma/Paraganglioma
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No Participants Registered
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-06-13
Primary completion date: 2020-09-03
Completion date: 2020-09-03
Clinical trial NCT02485990: Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)
Official title: An Open Label Dose Escalation/Expansion Study of Tremelimumab Alone or Combined With Olaparib for Recurrent or Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Withdrawal of sponsor support
Enrollment: 24.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-01-08
Primary completion date: 2020-03-05
Completion date: 2020-03-05
Clinical trial NCT03267888: Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Official title: Pilot Study of Pembrolizumab and Single-Fraction, Low-Dose, Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Sponsor: Emory University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 25.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-05-29
Primary completion date: 2022-09-02
Completion date: 2022-09-02
Plan to share individual participant data: NO
Clinical trial NCT04250337: Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.
Official title: A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
Acronym: ADhere
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 228.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-03
Primary completion date: 2021-08-11
Completion date: 2021-09-16
Baseline population: All randomized participants, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol.
Limitations and caveats: One investigational site with seventeen participants was excluded from analysis due to GCP issues.~Because of an error in the electronic data collection tool, the actual maximum score for each of the SCORAD symptoms was 9 instead of 10, resulting in a total maximum SCORAD score of 101 instead of 103. During the study, discussions with the SCORAD copyright owner resulted in a decision not to adjust the scale used or notify investigators as the altered scale was not expected to bias the results.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT03634683: A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation
Official title: A Phase I/II, Open Label, Single Arm, Multicenter Study of LioCyx in Subjects With Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma Post Liver Transplantation
Sponsor: Lion TCR Pte. Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Major changes in manufacturing process and investigational product
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-08-31
Primary completion date: 2022-08-31
Completion date: 2022-08-31
Clinical trial NCT03485911: Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Acronym: APeX-2
Sponsor: BioCryst Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 121.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-02-06
Primary completion date: 2019-04-10
Completion date: 2022-04-06
Baseline population: Intent to treat population
Plan to share individual participant data: NO
Clinical trial NCT03696537: IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT
Official title: A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) With Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
Sponsor: Indiana University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Extreme toxicity
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-08-29
Primary completion date: 2020-07-08
Completion date: 2021-04-13
Clinical trial NCT03509870: Bone Marrow Derived Allogeneic Mesenchymal Stromal Cells to Non-healing Diabetic Foot Wounds
Official title: Uncontrolled Non-randomised Single Dose Study of Topically Applied Bone Marrow Derived Allogeneic Mesenchymal Stromal Cells (REDDSTAR (ORBCEL-M)) in Patients With Non-healing Neuroischaemic Diabetic Foot Wounds'
Acronym: REDDSTAR
Sponsor: Steno Diabetes Center Copenhagen (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: study stopped because of lack of recruitment
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-06-01
Primary completion date: 2020-04-01
Completion date: 2020-04-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04186637: An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies
Official title: An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1)
Acronym: NEON-1
Sponsor: Alpine Immune Sciences, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 62.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-06-02
Primary completion date: 2022-11-09
Completion date: 2023-02-28
Clinical trial NCT03602976: Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis
Official title: A Single-center, Open Label, Cross-over Study on the Effects of Ursodeoxycholic Acid (UDCA) in Patients With Hepatic Sarcoidosis
Sponsor: University of Pennsylvania (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Inability to adequately recruit subjects in COVID-19 pandemic
Enrollment: 7.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-08-20
Primary completion date: 2022-01-12
Completion date: 2022-01-12
Baseline population: Number of subjects that completed observation period of 6 months
Limitations and caveats: Early termination due to poor recruitment in light of the COVID-19 pandemic, affecting data analysis.
Plan to share individual participant data: NO
Clinical trial NCT04114188: Tacrolimus After rATG and Infliximab Induction Immunosuppression (RIMINI)
Official title: Tacrolimus After rATG and Infliximab Induction Immunosuppression (RIMINI)
Acronym: RIMINI
Sponsor: Charite University, Berlin, Germany (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 68.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-12-15
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03829241: Randomized Trial of Adult Participants With Generalized Anxiety Disorder
Official title: A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of Troriluzole in Generalized Anxiety Disorder
Sponsor: Biohaven Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 881.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-19
Primary completion date: 2020-01-14
Completion date: 2020-05-08
Baseline population: Treated participants in the randomization phase: Enrolled participants who received at least 1 dose of blinded study therapy (troriluzole or placebo).
Plan to share individual participant data: NO
Clinical trial NCT04778397: Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
Official title: A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Patients With TP53 Mutant Acute Myeloid Leukemia
Acronym: ENHANCE-2
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study discontinued due to futility.
Enrollment: 258.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-07-01
Primary completion date: 2024-03-25
Completion date: 2024-03-25
Plan to share individual participant data: NO
Clinical trial NCT05361109: Baricitinib for Cutaneous Dermatomyositis
Official title: An Open-Label Pilot Study to Evaluate the Efficacy and Safety of Baricitinib in Subjects With Cutaneous Dermatomyositis
Sponsor: University of Washington (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Difficulty recruiting subjects
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-06-01
Primary completion date: 2023-03-31
Completion date: 2023-03-31
Clinical trial NCT04119011: Probiotics in Women With Primary Dysmenorrhoea
Official title: A Novel Approach to Manipulate Intestinal Homeostasis in Primary Dysmenorrhoea Women: a Randomised Controlled Trial
Sponsor: National University of Malaysia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 72.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-01
Primary completion date: 2020-03-31
Completion date: 2020-03-31
Plan to share individual participant data: YES
IPD sharing description: clinical data sheet containing demographics, data collection (pain score, quality of life questionnaire, pain diary)
IPD time frame: 20 months
Clinical trial NCT01101438: A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer
Official title: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Sponsor: Canadian Cancer Trials Group (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 3649.0 (ACTUAL)
Number of arms: 2.0
Start date: 2010-08-13
Primary completion date: 2021-09-21
Completion date: 2023-08-18
Baseline population: All randomized patients will be analyzed according to the arm that they were randomized to (intent to treat population).
Plan to share individual participant data: NO
Clinical trial NCT04740905: A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion
Official title: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion
Acronym: BALATON
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 553.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-02
Primary completion date: 2022-07-06
Completion date: 2023-06-12
Baseline population: ITT Population: All global participants who were randomized in the study, according to the assigned treatment.
Plan to share individual participant data: YES
IPD sharing description: For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Clinical trial NCT04738123: A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)
Official title: A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adults With DSM-5 Schizophrenia
Sponsor: Karuna Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 256.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-06
Primary completion date: 2022-11-29
Completion date: 2022-12-07
Plan to share individual participant data: NO
Clinical trial NCT03625687: Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant
Official title: Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Lack of funding, transitioned to standard of care
Enrollment: 19.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-02-05
Primary completion date: 2022-04-04
Completion date: 2022-04-04
Baseline population: Subjects receiving HCV RNA positive lung transplant and initiating treatment with DAA
Limitations and caveats: Study was terminated prior to completion and prior to meeting enrollment goal primarily due to lack of resources (staffing and funding) and transition of HCV-positive to HCV-negative lung transplants to standard of care. Full planned analysis was not completed due to enrollment number, however primary endpoint was assessed for all 16 subjects receiving treatment.
Plan to share individual participant data: YES
IPD sharing description: Anticipate to share coded data with collaborators
IPD time frame: Anticipate data would be available to share within 6 months after the final patient completes the study.
IPD access criteria: Coded data would be shared with collaborators who have received IRB approval to use the data and have been approved by the PI for their collaboration.
Clinical trial NCT04764851: Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates
Official title: A Phase 1, Open-Label, Fixed Sequence Drug-Drug Interaction Study to Evaluate the Effects of Repeat Doses of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport in Healthy Subjects
Sponsor: Emalex Biosciences Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: A number of subjects withdrew consent leaving the study without adequate power to achieve its primary end points.
Enrollment: 30.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-02-18
Primary completion date: 2021-04-02
Completion date: 2021-05-07
Plan to share individual participant data: NO
Clinical trial NCT05320393: Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
Official title: Phase II Multi-Ctr, Prospective, Randomized, Double Blind, Active-Controlled Single Treatment Increasing Dose Trial to Study Safety & Duration of Effect of 40U of PrabotulinumtoxinA-xvfs in Adult Subjects for Treatment of Glabellar Lines
Sponsor: Evolus, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 154.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-03-30
Primary completion date: 2023-05-22
Completion date: 2023-05-22
Plan to share individual participant data: NO
Clinical trial NCT00118209: Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Official title: Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas
Sponsor: Alliance for Clinical Trials in Oncology (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 524.0 (ACTUAL)
Number of arms: 2.0
Start date: 2005-05-31
Primary completion date: 2017-10-31
Completion date: 2021-11-15
Baseline population: Participants who completed the study in the Participant Flow are included in this analysis.
Clinical trial NCT03297463: Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
Official title: A Phase 1b/2 Study of Hypofractionated Radiation and Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
Sponsor: Masonic Cancer Center, University of Minnesota (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Replaced by another study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-01-31
Primary completion date: 2020-02-01
Completion date: 2020-02-01
Clinical trial NCT02145949: Mechanistic Approach to Preventing Atrophy and Restoring Function in Older Adults
Official title: Mechanistic Approach to Preventing Atrophy and Restoring Function in Older Adults
Sponsor: University of Oregon (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 80.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-12-31
Primary completion date: 2020-02-29
Completion date: 2020-02-29
Baseline population: 31 subjects in EAA group began study and 19 completed study. 36 subjects in placebo group began study and 20 completed study.
Clinical trial NCT05346653: The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure
Official title: The Hemodynamic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in Acute Decompensated Heart Failure
Sponsor: University of Chicago (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Enrollment goals were not met.
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-05-22
Primary completion date: 2023-05-23
Completion date: 2023-05-23
Baseline population: 1 subject consented to the study but was not randomized.
Plan to share individual participant data: NO
Clinical trial NCT03817554: Pramipexole for Restless Leg Syndrome in Peritoneal Dialysis Patients
Official title: A Randomized Controlled Trial of Pramipexole for Restless Leg Syndrome in Peritoneal Dialysis Patients
Sponsor: Peking University First Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The recruitment of participants in the study was difficulty.
Enrollment: 21.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-01
Primary completion date: 2020-08-31
Completion date: 2020-08-31
Plan to share individual participant data: NO